Merck, Moderna to Develop mRNA-Based Personalized Cancer Vaccines
Merck will pay Moderna $200M upfront through the partnership, which joins Merck’s immuno-oncology know-how with Moderna’s mRNA vaccine technology and GMP manufacturing capabilities
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
